CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.
In a phase 1 trial at the recommended phase 2 dose, 25 of 28 children, adolescents, and young adults with relapsed/refractory B-ALL achieved measurable residual disease-negative complete remission after bivalent CD19/CD22 CAR T-cell therapy, with most proceeding to HSCT and all three non-responders having non-CNS extramedullary disease.
Open original publication →What the AI sees
In a phase 1 trial at the recommended phase 2 dose, 25 of 28 children, adolescents, and young adults with relapsed/refractory B-ALL achieved measurable residual disease-negative complete remission after bivalent CD19/CD22 CAR T-cell therapy, with most proceeding to HSCT and all three non-responders having non-CNS extramedullary disease.
Research significance
The trial provides clinical evidence that CD19/CD22 bivalent CAR T cells can induce deep remissions and serve as a bridge to HSCT in relapsed/refractory B-ALL; it is reasonable but not proven to hypothesize that improved CD22 recognition or constructs optimized for extramedullary trafficking and activity could reduce antigen escape and improve responses in non-CNS extramedullary disease.
Source abstract
Multiantigen targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen targeting therapy. Our initial experience with a bivalent CD19.22.BBζ CAR T-cell construct in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL) demonstrated limitations in CD22 recognition, but a tolerable safety profile and efficacy prompted further evaluation. This trial enrolled patients between the ages of 3-39 with relapsed/refractory B-ALL. Following dose-escalation, patients who enrolled at the recommended phase 2 dose (RP2D) of 3×106 transduced CAR T cells/kg constitute this report. 30 CAYA were treated at the RP2D; 28 with B-ALL and 2 with Burkitt lymphoma. Across patients with B-ALL, 20 (71.4%) patients developed cytokine release syndrome (CRS); only 2 (10%) were grade >3. Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 3 (10.7%) patients; there were no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Following a protocol amendment to evaluate the efficacy of siltuximab as a first-line treatment of CRS, one patient received siltuximab with full resolution of CRS after two doses without needing additional anti-cytokine-directed therapies. A measurable residual disease-negative complete remission (CR) was attained in 25 (89.3%) patients, including 6 who had neither CRS nor ICANS. 23 patients (82.1%) proceeded directly to hematopoietic stem cell transplant (HSCT) following CAR T-cell infusion within a median of 51 days (range, 45-68 days), supporting the utility of this construct as a bridge to HSCT. All three non-responders had persistent non-central nervous system (CNS) extramedullary disease (EMD), although four of seven patients with non-CNS EMD achieved a CR. Median relapse-free survival among the 25 patients achieving CR was not reached, and the median overall survival for all 28 patients was 34 months (95% CI 17 to not estimable) from infusion. This extended experience demonstrates that CD19.22.BBζ CAR T-cell therapy is safe and clinically active, particularly as a bridge to HSCT. Non-response was confined to patients with non-CNS EMD, highlighting the persistent challenge of effectively targeting EMD and informing the design of future CAR constructs.Trial registration numberNCT03448393.